Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson in agreement with Burnham

Johnson and Johnson in agreement with Burnham

13th January 2009

Johnson & Johnson (J&J) has signed a licence agreement with Burnham Institute.

The deal – which will also see an assay development collaboration – will see Burnham providing access to high-throughput screening technologies.

It is hoped this will allow researchers to investigate certain drugs for the treatment of inflammatory diseases.

Dr John Reed, Burnham president and chief executive officer, professor and Donald Bren presidential chair, said the partnership “offers great synergies”.

He went on to note the company has “great expertise in finding new targets and screening compounds to identify chemical leads.”

“I believe this collaboration will foster the discovery of drug products with real clinical potential,” Dr Reed added.

Earlier this month, J&J said it had extended its tender offer for Mentor.

As a result of the added time given, all Mentor’s outstanding shares of common stock may now be purchased until January 16th, unless another extension is granted.

The offer was originally scheduled to expire on January 12th.

Founded in 1886, J&J expanded to England in 1924.

Its products include Listerine, Splenda and Johnson’s Bedtime.

In 1963, the company’s Ortho Pharmaceutical began marketing Ortho-Novum, the organisation’s first birth control pill.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.